Activity of some platinum(II/IV) complexes with edda-type ligands against human adenocarcinoma HeLa cells

Cisplatin analogues, cis-dichloro(ethylenediamine-N,N′-di-3-propanoic acid)platinum(II) (1) and cis-iodo(ethylenediamine-N,N′-di-3-propanoic acid)platinum(II) (2), as well as trans-dichloro-(ethylenediamine-N,N′-di-3-propanoato)platinum(IV) (3), trans-dibromo(ethylenediamine -N,N′-di-3-propanoato)platinum(IV) (4), trans-dichloro(propylenediamine-N,N′-diacetato)-platinum(IV) (5) and trans-dibromo(propylenediamine-N,N′-diacetato)platinum(IV) (6), -([Pt(H₂eddp)Cl₂], [Pt(Heddp)I], trans-[Pt(eddp)Cl₂], trans-[Pt(eddp)Br₂], trans-[Pt(pdda)Cl₂] and trans-[Pt(pdda)Br₂], respectively) were used to assess antitumor selectivity against human adenocarcinoma HeLa cells. The results show that different oxidation states of platinum, different halide ligands, chelating aminocarboxylato and diamine backbones have similar effects with edda-type ligands and activity is lower than for cisplatin.